Contamination issues in the pharmaceutical industry identified during visual inspection or responding to FDA inquiries have led companies to consider particulate matter testing early in product development. DDL’s team of engineers can help identify if foreign particles exist in your combination product during any phase of product development.
USP 787 Subvisible Particulate Matter in Therapeutic Protein Injections
USP 788 Particulate Matter in Injections
ISO 8536 Infusion Equipment for Medical Use
Contact us for more information or to talk to an engineer.
